Exact Sciences to Present New Oncotype DX Genomic Prostate Score® Test Data and Exhibit its Full Urology Portfolio at the 2021 Virtual AUA Annual Meeting
New analysis of the SEER registry and the Oncotype DX® GPS™ assay highlights the test’s clinical utility in helping guide treatment decisions at the time of diagnosis
MADISON, Wis., September 2, 2021 – Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the company will present new data and exhibit its portfolio of prostate cancer genomic tests at its virtual booth, during the American Urological Association’s Annual (AUA 2021) Meeting, being held September 10-13. This is the first AUA meeting where Exact Sciences will feature its full Oncotype® portfolio of urology genomic assays, including the Oncotype DX Genomic Prostate Score® (GPS™) test for localized prostate cancer; the Oncotype MAP™ Pan-Cancer Tissue test for solid tumors, including advanced prostate cancer; and the Oncotype DX AR-V7 Nucleus Detect® test for metastatic castration-resistant prostate cancer. An analysis of the SEER registry presented at the meeting will reinforce the value of the Oncotype DX® GPS test in helping guide treatment decisions in clinically low-risk prostate cancer patients.
“With clinical outcomes data across 15 publications and in more than 5,000 men, the Oncotype DX GPS test is one of the most rigorously studied assays in localized prostate cancer. The data we’re presenting at AUA once again highlight its clinical utility in helping physicians and patients decide between active surveillance and definitive treatment,” said Rick Baehner, chief medical officer of Precision Oncology for Exact Sciences. “We’re also thrilled to showcase our entire prostate cancer portfolio, supporting early to late-stage patient care, while connecting with our collaborators in the urology and oncology community.”
Key AUA activities featuring the Oncotype portfolio during the meeting include:
